Many of us are opposed to a RS especially 1 share for every

New Post Public Reply Private Reply Replies (3) Message Board
Taber Disco Bob #55034
Many of us are opposed to a RS especially 1 share for every 15 or higher! I've stated it in the past that I would still frown upon one that was 10:1. I think if they do one like a 5:1 or 6:1 could be tolerable, and they would be able to accomplish the same things! Any higher, a smart investor needs to deeply question NTEK's agenda... Especially with the new revenue coming in.
1

Nanotech Entertainment Inc. (NTEK) Stock Research Links

NTEK Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bay Area to Host New Jerry Garcia Arts Center

Updated Category News Views 84

Celebrating a Legend in the Heart of San Francisco The Bay Area is set to become home to a vibrant new center dedicated to celebrating the multifaceted legacy of Jerry Garcia, Grateful Dead co-founder. Announced by the Garcia family, with the help of archival platform Starchive and project coordinator Christopher McCutcheon, the Jerry Garcia Music Arts Center promises to...

Continue Reading
Howard Hughes Joins S&P SmallCap 600, Arcosa Out

Updated Category News Views 45

Shakeup in the S&P SmallCap 600 It’s one of those days where something shifts in the market landscape—Howard Hughes Holdings Inc. (NYSE: HHH) is swaggering into the S&P SmallCap 600. Kicking off on October 28, it's got quite the entrance lined up. On the other end, Arcosa Inc. (NYSE: ACA) is making a hasty exit after getting scooped up by CRH plc (NYSE: CRH). For...

Continue Reading
Hansa's Idefirix Shows Promise for Kidney Transplants

Updated Category News Views 22

Compelling Progress from Hansa Biopharma Y'know, navigating through the biotech jungle isn't for the faint-hearted. Hansa Biopharma's recent results with Idefirix could just be the beacon of hope for patients struggling on transplant lists. Announced at the ASN Kidney Week—a name that's got weight, by the way—these findings aren't just filling space. They're promising...

Continue Reading
Bio-Thera's New Data: A Game Changer for NSCLC?

Updated Category News Views 129

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Continue Reading
Anavex Faces Securities Lawsuit: Investor Implications

Updated Category News Views 59

Storm Clouds Over Anavex: What Investors Need to Know If you've got a slice of Anavex Life Sciences Corp. (NASDAQ: AVXL) in your portfolio, the latest chapter of their legal saga feels less like a twist and more like a twist of the knife. These lawsuits often come out of left field for investors, but this one seems like a slow train that’s been gathering steam for a...

Continue Reading
The Big Greek Café Stakes a Claim at Westview Promenade

Updated Category News Views 89

Breaking into Westview Promenade The Big Greek Café is making a bold play in Frederick County, Maryland, choosing Westview Promenade for its second local spot. You know they're not just picking any old place; they're setting up shop at a bustling 200,000 square foot lifestyle center. This expansion marks a significant move as they join hands with Hill Management Services...

Continue Reading
Unicycive Faces Legal Heat Amid Stock Tumble

Updated Category News Views 22

Unicycive Therapeutics' Rough Ride In this wild market, sometimes even the most seasoned investors get blindsided. Unicycive Therapeutics (NASDAQ: UNC) shareholders are currently caught in a storm with their stock nose-diving by 39.1% on June 30, 2026. It's like being taken to the cleaners without the decency of a warning. Failed Expectations & FDA Blues Here's the...

Continue Reading
Likang's Bold Move: Cancer Immunotherapy at AD Summit

Updated Category News Views 42

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Continue Reading
Lilly's Sofe-M Shakes Up Ovarian Cancer Treatment

Updated Category News Views 173

Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....

Continue Reading
Mahomes Faces Pressure to Ditch AIRSHARE After Tragedy

Updated Category News Views 40

Patrick Mahomes and the AIRSHARE Dilemma When the air turns turbulent, even the lucky stars often tremble. Kansas City Chiefs’ star quarterback, Patrick Mahomes, finds himself smack in the eye of such a storm. With a name as illustrious as his, the links to AIRSHARE, a private jet provider caught in the crosshairs of tragedy, create more than just a PR hiccup—they...

Continue Reading

Top 5 Most Recently Viewed Articles

China Opportunity 2.0: Global Growth Through Innovation

Updated Category News Views 16

China's Strategic Shift: Evolution of Opportunity Ever find yourself mulling over the phrase "China opportunity 2.0"? It's not just a catchy phrase thrown around at the 17th Summer Davos. No, it's a seismic shift in how the world views China's global significance. This isn't the old "China opportunity," all about just the size of the market and low production costs. We're...

Continue Reading
Peabody Announces Upcoming Financial Results for Q3 2024

Updated Category News Views 119

Peabody to Reveal Q3 2024 Financial Results On October 31, Peabody (NYSE: BTU) will publicly announce its financial results for the third quarter of 2024. Investors and analysts alike are keenly interested in the outcomes and implications of this announcement, which is a reflection of the company’s performance in a competitive energy market. Conference Call Details...

Continue Reading
EuroDry CEO to Present at Noble Capital Markets' Event

Updated Category News Views 112

EuroDry Ltd. Set to Showcase at Emerging Growth Virtual Conference EuroDry Ltd., a respected owner and operator of drybulk vessels, has announced its participation in a significant event that's drawing attention from both maritime and investment circles. This company, which specializes in the transportation of drybulk cargoes, is excited to take part in the upcoming Noble...

Continue Reading
Transforming AI Infrastructure with Run:ai and Dell Technologies

Updated Category News Views 374

Streamlining AI Infrastructure Management In today's fast-paced technological landscape, businesses are increasingly leveraging artificial intelligence to enhance their operations. Run:ai, a pioneering company in AI orchestration, has undertaken a significant collaboration with Dell Technologies to revolutionize the deployment and management of AI infrastructure for...

Continue Reading
Shawna Vanaken Transitions to Avantax for Enhanced Services

Updated Category News Views 159

Shawna Vanaken Joins Avantax Community for Enhanced Services Cetera is thrilled to announce that Shawna Vanaken, a dedicated financial advisor with extensive experience, has transitioned from Commonwealth to become part of Avantax, a community of tax-focused financial professionals. This move represents a significant step for her and her team at Pinnacle Tax & Financial...

Continue Reading